Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
Journal article published in 2019 by
Maria Di Bartolomeo 
,
Monica Niger ,
Federica Morano,
Salvatore Corallo,
Maria Antista,
Stefano Tamberi,
Sara Lonardi,
Samantha Di Donato,
Rossana Berardi,
Mario Scartozzi,
Giovanni Gerardo Cardellino,
Francesco Di Costanzo,
Lorenza Rimassa ,
Alberto Gianluigi Luporini,
Raffaella Longarini
and other authors.
,
Monica Niger ,
Federica Morano,
Salvatore Corallo,
Maria Antista,
Stefano Tamberi,
Sara Lonardi,
Samantha Di Donato,
Rossana Berardi,
Mario Scartozzi,
Giovanni Gerardo Cardellino,
Francesco Di Costanzo,
Lorenza Rimassa ,
Alberto Gianluigi Luporini,
Raffaella Longarini
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 